Abstract
Recently, Molecular Communication (MC) has been recognized as an enabling technology for nanonetworks where MC is envisioned to enable nanorobots to achieve sophisticated and complex tasks in the human body for promising medical applications. Many MC methods that can be applied in the human body have been proposed and modeled in the literature. However, none of them can be used to convey information between distant points that are separated by body fluids, tissues, or placed in different organs. In this paper, we propose a new method and system for Molecular Communication in the Body, denoted MoSiMe and MoCoBo, respectively. The method takes advantage of how the absorption, distribution, metabolization, and elimination (ADME) bodily processes affects drugs, referred to as Pharmacokinetics (PK) in pharmacology, to enable MC between any points of the human body regardless of their distance even if they are in different parts of the body and separated by tissues and fluids. The architecture, design and components of the MoCoBo system and MoSiMe method are described and different transmitter designs, including a novel passive transmitter design for the first time in telecommunications, are introduced. An analytical model for the body channel is derived and validated with respect to existing human and animal tests. The model captures the ADME bodily processes that affect the kinetics of substances administered to the body. Additionally, an experimental MoCoBo proof of concept platform, capable of reliably sending and receiving a stream of bits between a transmitter and a receiver, is built and validated against clinical trials, animal tests and analytical models. The introduced platform can also be utilized to test modulation techniques and designs for new MoCoBo transmitters and receivers.
Introduction
The field of nanomedicine envisions swarms of nanorobots performing targeted drug delivery or localized surgery. For these agents to coordinate, they require a robust communication framework. Traditional Molecular Communication (MC) methods typically rely on simple diffusion or diffusion-with-drift in the bloodstream. While effective at microscopic scales, these methods fail when communication is required between distant organs separated by complex tissue barriers. This research introduces MoCoBo (Molecular Communication in the Body) and MoSiMe (Molecular Signaling Method), which leverage the body's natural metabolic processes to bridge this long-range gap.
System Architecture and the Body Channel
MoCoBo treats the entire human body as a communication channel. By utilizing the principles of Pharmacokinetics (PK), specifically the ADME (Absorption, Distribution, Metabolism, and Elimination) cycle, the system can transmit information between any two points in the body.
In this architecture, the body is modeled as a Linear Time-Invariant (LTI) system. An administered substance acts as the input signal, and its concentration over time at a distant site serves as the output. This allows researchers to apply standard telecommunication techniques, such as deconvolution, to recover data from the naturally dispersed concentration curves.
Pharmacokinetic Modeling (MoSiMe)
The MoSiMe method relies on mathematical models of how substances move through the body. The researchers derived impulse responses for different administration scenarios.
As shown in Figure 2, the models account for:
- Absorption ($k_a$): The rate at which the substance enters the systemic circulation from the administration site.
- Elimination ($k_e$): The rate at which the body removes the substance. This "falling phase" of the concentration curve is critical for resetting the channel for subsequent bits.
Novel Transmitter Designs
The paper introduces two primary transmitter types:
- Active Transmitters: These use microcontrollers and pumps to actively release molecules into the body.
- Passive Transmitters: A novel concept in telecommunications, these "smart pills" or patches use biodegradable layers of varying thicknesses. As these layers dissolve at predetermined intervals, they release molecular pulses, creating a modulated signal without the need for internal batteries.
Experimental Validation and Results
The MoCoBo system was validated using both clinical data and a physical testbed.
- Model Validation: The LTI model was tested against human clinical data (Chlorphenesin Carbamate) and rat data (Vinpocetine), showing a high degree of accuracy in predicting concentration profiles.
- Physical Testbed: A proof-of-concept platform using salt-water conductivity sensors successfully transmitted an 11-bit sequence (111-01010011), demonstrating that the system can reliably convey digital information through a biological-like environment.
Conclusion and Future Outlook
MoCoBo represents a paradigm shift in molecular communication by utilizing the body's metabolism as a modem. While current data rates are limited by the speed of biological elimination processes, the system's distance-independence and the potential for passive, battery-free transmitters offer a promising path for future nanomedical applications. Future research will focus on increasing data rates, ensuring molecular biocompatibility, and developing more complex multi-compartment models to better reflect human physiology.
Summary updated